TC BioPharm (Holdings) plc financial data

Symbol
TCBP, TCBPW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Maxim 1, 2 Parklands Way, Holytown, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
TC BioPharm (Holdings) Ltd (to 12/23/2021)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Operating Margin -314 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.9 M shares
Common Stock, Shares, Outstanding 63.9 M shares
Entity Public Float 3.1 M USD
Common Stock, Value, Issued 6.39 K GBP
Weighted Average Number of Shares Outstanding, Basic 30.1 M shares +1369%
Weighted Average Number of Shares Outstanding, Diluted 30.1 M shares +1369%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.84 M GBP
Research and Development Expense 1.3 M GBP -32.8%
General and Administrative Expense 2.14 M GBP -3.98%
Operating Income (Loss) -3.44 M GBP +17.4%
Nonoperating Income (Expense) 7.24 M GBP -20%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.43 M GBP -232%
Income Tax Expense (Benefit) -111 K GBP +72.3%
Net Income (Loss) Attributable to Parent -3.32 M GBP -423%
Earnings Per Share, Basic -0.11 GBP/shares +64.5%
Earnings Per Share, Diluted -0.11 GBP/shares +64.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 981 K GBP
Assets, Current 4.2 M GBP
Property, Plant and Equipment, Net 1.16 M GBP
Operating Lease, Right-of-Use Asset 1.29 M GBP
Intangible Assets, Net (Excluding Goodwill) 609 K GBP
Assets 7.26 M GBP
Accounts Payable, Current 1.93 M GBP
Accrued Liabilities, Current 1.01 M GBP
Liabilities, Current 4.76 M GBP
Operating Lease, Liability, Noncurrent 1.42 M GBP
Liabilities 6.18 M GBP
Retained Earnings (Accumulated Deficit) -42.2 M GBP
Stockholders' Equity Attributable to Parent 1.08 M GBP -3.24%
Liabilities and Equity 7.26 M GBP

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.41 M GBP +17.3%
Net Cash Provided by (Used in) Financing Activities 933 K GBP -76.4%
Net Cash Provided by (Used in) Investing Activities -5.62 K GBP +96.1%
Common Stock, Shares Authorized 63.9 M shares
Common Stock, Shares, Issued 63.9 M shares
Common Stock, Par or Stated Value Per Share 0 GBP/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.48 M GBP -265%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 981 K GBP -82.8%
Deferred Tax Assets, Valuation Allowance 4.45 M GBP -7.44%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.24 pure +21.1%
Deferred Tax Assets, Gross 4.45 M GBP -7.44%
Operating Lease, Liability 1.73 M GBP
Depreciation 115 K GBP -32.2%
Payments to Acquire Property, Plant, and Equipment 110 K GBP -54.2%
Property, Plant and Equipment, Gross 5.43 M GBP
Operating Lease, Liability, Current 308 K GBP
Lessee, Operating Lease, Liability, to be Paid, Year Two 447 K GBP
Lessee, Operating Lease, Liability, to be Paid, Year One 447 K GBP
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 434 K GBP
Lessee, Operating Lease, Liability, to be Paid, Year Three 447 K GBP
Lessee, Operating Lease, Liability, to be Paid, Year Four 447 K GBP
Operating Lease, Payments 112 K GBP 0%
Additional Paid in Capital 42.8 M GBP
Current Federal Tax Expense (Benefit) 1.09 M GBP -36.7%
Amortization of Intangible Assets 12.3 K GBP +3.9%
Interest Expense 83 K GBP -98.8%